10x Genomics (TXG) Cash & Equivalents (2018 - 2026)

10x Genomics has disclosed Cash & Equivalents across 9 years of filings, most recently posting $490.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $490.3 million, up 30.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $490.3 million (up 30.03% YoY), and the FY2025 annual result was $474.0 million, up 37.75% from the prior year.
• Cash & Equivalents came in at $490.3 million for Q1 2026 at 10x Genomics, up from $474.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $490.3 million in Q1 2026 to a low of $219.7 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $355.8 million (2024), against an average of $354.0 million.
• Across the five-year window, Cash & Equivalents slumped 62.59% in 2022 and soared 63.5% in 2023, its largest moves.
• 10x Genomics' Cash & Equivalents stood at $219.7 million in 2022, then soared by 63.5% to $359.3 million in 2023, then fell by 4.24% to $344.1 million in 2024, then jumped by 37.75% to $474.0 million in 2025, then climbed by 3.44% to $490.3 million in 2026.
• The last three Cash & Equivalents figures came in at $490.3 million (Q1 2026), $474.0 million (Q4 2025), and $432.5 million (Q3 2025), per Business Quant data.